BeiGene, Ltd. $800 Million Public Offering

Davis Polk advised the joint book-running managers and representatives of the underwriters in the $800 million public offering by BeiGene, Ltd. of American depositary shares. The ADSs are listed on the NASDAQ Global Select Market under the symbol “BGNE.”

BeiGene is a global, commercial-stage, research-based biotechnology company focused on molecularly targeted and immuno-oncology cancer therapeutics.

The Davis Polk corporate team included partner Bruce K. Dallas and associates Jeffrey C. Lau, Dongbiao Shen and Stephanie Y. Cheng. Partner Rachel D. Kleinberg and associate Omer Harel provided tax advice. The intellectual property and technology team included partner Pritesh P. Shah and associate Paul S. Lee. Partner Nora M. Jordan provided Investment Company Act and Investment Advisers Act advice. Counsel Marcie A. Goldstein provided FINRA advice. Members of the Davis Polk team are based in the Northern California, New York and London offices.